Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience
T-DXd represents a cost-effective alternative to T-DM1 as a second-line treatment for HER2-positive MBC in Iran. Its clinical advantages, combined with an ICER below the local WTP threshold, support its adoption in this patient population.
Authors
- Bita Shahrami (ORCID: https://orcid.org/0000-0002-5383-782X)
- Yalda Metghalchi
- Neda Yaghoubi (ORCID: https://orcid.org/0000-0002-0466-9903)
- Behzad Fatemi (ORCID: https://orcid.org/0000-0001-7912-7546)
- Soheila Rezaei (ORCID: https://orcid.org/0000-0001-9077-6715)
- Razieh Ahmadi
- Mohammad Vaezi (ORCID: https://orcid.org/0000-0002-3186-5491)
Institutions
- Shahid Beheshti University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2025-05-17
- DOI
- https://doi.org/10.1186/s12913-025-12876-6
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09